A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, fund raising and appointments, here’s a quick look at which stocks will be in focus in today's ...

J.P. Morgan analyst James Gordon has maintained their bullish stance on AZN stock, giving a Buy rating on September 20. James Gordon has given his Buy rating due to a combination of factors ...

The experimental drug Astrazeneca used against breast cancer has proven not to work as hoped. The stock, listed in London, is ...

Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...